Seelos Therapeutics Announces Proposed Public Offering of Common Stock
2020年3月12日 - 5:15AM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today that it has commenced a proposed underwritten public offering
of shares of common stock. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed or as to the actual size or
terms of the offering. In addition, the Company intends to grant
the underwriters an option to purchase up to an additional 15% of
the aggregate number of shares of common stock sold in the offering
on the same terms and conditions to cover over-allotments, if any.
All of the shares of common stock in the offering will be sold by
Seelos.
Benchmark Company is acting as sole book-running
manager for the offering.
Seelos intends to use the net proceeds from the
offering for general corporate purposes and to advance the
development of its product candidates.
The securities described above will be offered
by Seelos pursuant to an effective “shelf” registration statement
on Form S-3 (File No. 333-221285) previously filed with the
Securities and Exchange Commission (the “SEC”) on November 2, 2017,
amended on December 1, 2017, and declared effective by the SEC on
December 7, 2017. The securities may be offered only by means
of a prospectus. A preliminary prospectus supplement and the
accompanying prospectus relating to and describing the offering
will be filed with the SEC. Electronic copies of the preliminary
prospectus supplement and the accompanying prospectus may be
obtained by visiting the SEC’s website at www.sec.gov or by
contacting The Benchmark Company, LLC, Attn: Prospectus Department,
150 E. 58th Street, 17th floor, New York, NY 10155, by calling
(212) 312-6700 or by e-mail at prospectus@benchmarkcompany.com.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel therapeutics
to address unmet medical needs in central nervous system (CNS)
disorders and other rare orphan disorders. The Company's robust
portfolio includes several late-stage clinical assets. The target
indications include Acute Suicidal Ideation and Behavior (ASIB) in
Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder
(PTSD), Sanfilippo syndrome, Parkinson’s Disease and other
psychiatric and movement disorders.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward-Looking Statements:
This press release contains forward-looking
statements related to Seelos Therapeutics, Inc. and its
subsidiaries under the safe harbor provisions of Section 21E of the
Private Securities Litigation Reform Act of 1995 and subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. Forward-looking statements include
statements regarding the proposed underwritten public offering and
the anticipated use of proceeds from the offering and other matters
that are described in Seelos’ most recent periodic reports filed
with the SEC, including Seelos’ Annual Report on Form 10-K for the
year ended December 31, 2018 filed on March 28, 2019, subsequent
Quarterly Reports on Form 10-Q and the preliminary prospectus
supplement and the accompanying prospectus related to the proposed
public offering filed with the SEC on March 11, 2020, including
risks and uncertainties associated with general economic and market
conditions and the satisfaction of customary closing conditions and
the other risk factors set forth in those filings. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release and
Seelos disclaims any intent or obligation to update these
forward-looking statements except as required by law.
Contact Information: Anthony Marciano Head of
Corporate Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 6 2024 まで 7 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 7 2023 まで 7 2024